ACM
EW icon

Asymmetry Capital Management’s Edwards Lifesciences EW Stock Holding History

Asymmetry Capital Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-30,600
Closed -$956K – 29
2016
Q4 		$956K Sell
30,600
-11,124
-27% -$360K 1.78% 16
2016
Q3 		$1.68M Sell
41,724
-43,086
-51% -$1.62M 2.92% 14
2016
Q2 		$2.82M Buy
84,810
+37,470
+79% +$1.28M 5.16% 9
2016
Q1 		$1.39M Sell
47,340
-94,350
-67% -$2.6M 3.63% 12
2015
Q4 		$3.73M Sell
141,690
-23,754
-14% -$617K 5.64% 8
2015
Q3 		$3.92M Buy
+165,444
New +$3.99M 8.73% 2

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Winslow Capital Management
Winslow Capital Management Minneapolis, Minnesota $25.6B AUM 33.75% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Asymmetry Capital Management's EW Position: Q1 2017 in Review

Asymmetry Capital Management sold out of Edwards Lifesciences (EW) in Q1 2017, closing a stake of 30,600 shares — an estimated $956K sold.

Asymmetry Capital Management first reported a position in EW in Q3 2015 and held it in 6 quarters. The position peaked at $3.92M in Q3 2015. 690 funds tracked by Wall St. Rank hold EW as of Q1 2017.

  • Asymmetry Capital Management reported no remaining Edwards Lifesciences position as of Q1 2017 after selling out during the quarter.
  • Asymmetry Capital Management sold 30,600 Edwards Lifesciences shares in Q1 2017, an estimated $956K.
  • Asymmetry Capital Management first reported a position in Edwards Lifesciences in Q3 2015 and held it in 6 quarters.
  • Asymmetry Capital Management's Edwards Lifesciences position peaked at $3.92M in Q3 2015.
  • 690 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2017.

Based on Asymmetry Capital Management's 13F filing for Q1 2017, filed 12 May 2017.